BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate,...
BC Week In Review | Jan 18, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Extra | Jan 17, 2019
Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest the HDAC inhibitor entinostat alone or in combination with chemotherapy could help treat alveolar rhabdomyosarcoma. In an orthotopic mouse model of alveolar rhabdomyosarcoma, entinostat decreased tumor growth compared with vehicle,...
BC Week In Review | Dec 14, 2018
Clinical News

Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus...
BC Innovations | Nov 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest miR-584-5p could help treat medulloblastoma. In patient tissue samples or tumor cells from patient-derived xenograft (PDX) mouse models of medulloblastoma, miR-584-5p levels were lower...
BC Week In Review | Oct 5, 2018
Clinical News

Adcetris meets in Phase III for first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin plus chemotherapy met the primary and all key secondary endpoints in the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing...
BC Innovations | Jun 6, 2018
Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
BioCentury | Apr 13, 2018
Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
BC Innovations | Dec 6, 2017
Emerging Company Profile

Building up nerve

AxoSim Technologies LLC has developed a 3-D human nerve-on-a-chip platform to recapitulate the in vivo organization of nerve bundles with greater fidelity to human systems than competitor models. The service provider is positioning its system...
Items per page:
1 - 10 of 343